Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Novel Combinations in mRCC: Axi/Pembro vs Axi/Avelumab

March 29th 2019

Goals in Previously Treated Advanced Renal Cell Carcinoma

March 29th 2019

Selecting an Optimal Second-Line Regimen for mRCC

March 29th 2019

Frontline Therapy for mRCC: Sequencing and Goals

March 29th 2019

Evaluating I-O Monotherapy's Value in Treating mRCC

March 29th 2019

mRCC: Identifying and Managing AEs in TKIs and IO Therapy

March 29th 2019

Role of TKIs in Intermediate or Poor-Risk mRCC

March 29th 2019

Favorable-Risk mRCC: Choosing Appropriate Frontline Therapy

March 29th 2019

Risk Stratification in Metastatic Renal Cell Carcinoma

March 29th 2019

Dr. Tagawa Discusses Darolutamide in CRPC

March 28th 2019

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian-Weill Cornell Medical Center, discusses darolutamide in castration-resistant prostate cancer.

Dr. Higano on Role of PARP Inhibitors in Prostate Cancer

March 26th 2019

Celestia Higano, MD, FACP, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, professor, Department of Medicine and Urology, University of Washington, Seattle Cancer Care Alliance, discusses the role of PARP inhibitors in prostate cancer.

ADT and the Need for a Multidisciplinary Approach

March 25th 2019

Optimizing Prevention of MACEs in Prostate Cancer

March 25th 2019

Standard of Care in Metastatic Prostate Cancer

March 25th 2019

Real-World Patients With High Risk of MACEs

March 25th 2019

GnRH Antagonists Versus GnRH Agonists

March 25th 2019

Effects of ADT on Morbidity and Mortality

March 25th 2019

Data Supporting the Risk of MACEs in ADT

March 25th 2019

Adverse Effects of Hormone Therapy in Prostate Cancer

March 25th 2019

The Cardioprotective Role of Androgens

March 25th 2019